Overview
Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis
Status:
Active, not recruiting
Active, not recruiting
Trial end date:
2021-11-01
2021-11-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to assess the efficacy of etrasimod on clinical remission in participants with moderately to severely active ulcerative colitis (UC).Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Arena Pharmaceuticals
Criteria
Inclusion Criteria:- Diagnosed with ulcerative colitis (UC) ≥ 3 months prior to screening
- Active UC confirmed by endoscopy
Exclusion Criteria:
- Severe extensive colitis
- Diagnosis of Crohn's disease (CD) or indeterminate colitis or the presence or history
of a fistula consistent with CD
- Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis